» Articles » PMID: 19906761

Randomized Phase III Trial Comparing Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine As First-line Treatment in Women with Advanced Breast Cancer

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2009 Nov 13
PMID 19906761
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The purpose of this study was to compare docetaxel plus epirubicin versus docetaxel plus capecitabine combinations as front-line treatment in women with advanced breast cancer (ABC).

Patients And Methods: Previously untreated patients with ABC were randomly assigned to receive docetaxel 75 mg/m(2) plus epirubicin 75 mg/m(2) (DE) on day 1 or docetaxel 75 mg/m(2) on day 1 plus capecitabine 950 mg/m(2) orally twice daily on days 1-14 (DC) in 21-day cycles. Previous anthracycline-based (neo)-adjuvant chemotherapy was allowed if completed >1 year before enrollment. The primary objective of the study was to compare time to disease progression (TTP).

Results: One hundred and thirty-six women were treated on each arm and median TTP was 10.6 versus 11.0 months (P = 0.7), for DE and DC, respectively. According to RECIST criteria we observed 15 (11%) versus 11 (8%) complete responses and 55 (40%) versus 61 (45%) partial responses (P = 0.8), with DE and DC, respectively. Severe toxicity included grade 3-4 neutropenia (57% versus 46%; P = 0.07), febrile neutropenia (11% versus 8%; P = 0.4), hand-foot syndrome (0% versus 4%; P = 0.02), grade 2-3 anemia (20% versus 7%; P = 0.001) and asthenia (12% versus 6%; P = 0.09) with DE and DC, respectively.

Conclusions: The DE and DC regimens have similar efficacy but different toxicity. Either regimen can be used as front-line treatment of ABC.

Citing Articles

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis.

Wu J, Wang Z, Fu Y BMC Womens Health. 2025; 25(1):104.

PMID: 40055784 PMC: 11887160. DOI: 10.1186/s12905-025-03628-z.


Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons.

Zeng H, Lv H, Zhang M, Niu L, Wang J, Sun H J Cancer Res Clin Oncol. 2025; 151(2):89.

PMID: 39979499 PMC: 11842397. DOI: 10.1007/s00432-025-06133-w.


Role and efficacy of capecitabine in the anthracycline-free regimen in breast cancer patients: a systematic review and meta-analysis.

Wang S, Deng L, Chen J, Li Y, Zhong Y, Wang Y J Cancer Res Clin Oncol. 2023; 149(19):17671-17682.

PMID: 37891407 DOI: 10.1007/s00432-023-05459-7.


Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial.

Li D, Tao Z, Wang B, Wang L, Cao J, Hu X NPJ Breast Cancer. 2022; 8(1):110.

PMID: 36127351 PMC: 9489776. DOI: 10.1038/s41523-022-00462-6.


Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.

Hoon S, Lau P, White A, Bulsara M, Banks P, Redfern A Cochrane Database Syst Rev. 2021; 5:CD011220.

PMID: 34037241 PMC: 8150746. DOI: 10.1002/14651858.CD011220.pub2.